Today: 3 July 2026
HSBC share price ticks up in London as Asia rally and results countdown focus traders
9 February 2026
2 mins read

HSBC share price ticks up in London as Asia rally and results countdown focus traders

London, Feb 9, 2026, 08:01 GMT — Regular session

HSBC Holdings Plc moved up in early London hours Monday, echoing gains across Asia and a rebound in its Hong Kong shares. The stock (HSBA.L) climbed 0.5% to 1,311.8 pence by 0801 GMT, hovering close to its 52-week peak after February’s rocky opening.

The clock is ticking. HSBC’s annual results are coming up in under three weeks—a key event for a stock that’s been on a tear and now looks set for more hefty capital returns. The bank’s Annual Results 2025 drop Feb. 25, with a morning investor and analyst briefing in London on the schedule.

Traders are weighing if HSBC’s momentum holds up as bets on rate cuts gather steam and investors begin sorting through global banks for standouts. Put simply: as rates slip, net interest income—the spread banks pocket from loans versus deposits—can come under pressure, though fee income from deals and wealth management might pick up.

Shares of HSBC (0005.HK) climbed roughly 3.2% late in the Hong Kong session, trading at HK$139.10. Over in New York, the bank’s ADRs (HSBC) last finished at $89.29 after U.S. markets closed on Friday. HSBC’s share-price dashboard, reflecting activity from all three listings, indicated these levels—though with a minimum 15-minute delay.

Asian stocks rallied, with sentiment buoyed by Japanese Prime Minister Sanae Takaichi’s election win—it’s sparked speculation about fresh stimulus measures. A late-week bounce in U.S. chip names also offered support. “The victory gives Takaichi a stable majority, enabling decisive action on fiscal stimulus, AI, semiconductors, energy security, and strategic reforms,” said Marc Jocum, senior investment strategist at Global X ETFs Australia. Reuters

HSBC usually feels that kind of sentiment before others, thanks to its big presence in Hong Kong and its reputation as a bellwether for London-listed, Asia-focused profits. The stock often reacts to changes in currency or rate forecasts, even if there’s nothing specific out from the company that day.

UK bank shares are watching for signals from sector counterparts. On Monday, NatWest agreed to acquire Evelyn Partners, the wealth manager, in a transaction that puts a 2.7 billion pound tag on the business—including its debt. The lender also rolled out a 750 million pound share buyback tied to the deal. It’s a fresh sign of banks chasing fee-based revenue as broader conditions shift.

For HSBC, the immediate drivers are clear-cut: earnings, guidance, and capital decisions. Shareholders will be listening for management’s take on distributions, cost trends, and loan demand prospects in core regions. There’s also interest in fresh details on capital deployment following several major strategy shifts in recent years.

Still, not every risk on the horizon ties back to next quarter’s results. ShareAction, the campaign group, says it’s gearing up to examine climate pledges from major banks and prod investors to confront chairs who appear to be wavering—HSBC is on its target list. That could turn up the heat as AGM season approaches.

HSBC is set to remain caught between macro sentiment and earnings expectations for now. Attention turns to London’s cash open, with traders eyeing whether the initial move sticks as morning liquidity ramps up.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Mesoblast (ASX:MSB) gains 9.3% as FDA accepts modular review of Rexlemestrocel-L BLA
    July 3, 2026, 1:10 PM EDT. Shares of Mesoblast (ASX:MSB) rose 9.3% after the FDA agreed to review its Biologics License Application for rexlemestrocel-L. The therapy, aimed at stopping gastrointestinal bleeding in end-stage heart failure patients on LVADs, will follow a modular review process under FDA's flexible pathway for rare, high-mortality diseases. Mesoblast landed US$50 million in new funding recently, giving it more time to run late-stage trials. The company is still counting on trial results and regulatory progress before it can turn a profit. Analysts see possible revenue of A$485.4 million and earnings of A$222.1 million by 2029, but say there's still plenty of risk.
Windows 11 printer alert: Microsoft tightens the screws on legacy V3/V4 drivers in 2026
Previous Story

Windows 11 printer alert: Microsoft tightens the screws on legacy V3/V4 drivers in 2026

Wells Fargo & Company stock drops 2% as CFO talks loan growth — what traders watch next
Next Story

Wells Fargo & Company stock drops 2% as CFO talks loan growth — what traders watch next

Go toTop